Drug-eluting metallic stents in urology

Kallidonis, Panagiotis; Georgiopoulos, Ioannis; Kyriazis, Iason; Al-Aown, Abdulrahman; Liatsikos, Evangelos

doi:10.4103/0970-1591.124198

Cited by 7 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improvement of the outcome is based on the release of a cytostatic drug that inhibits neo-intimal hyperplasia, which is responsible for the re-stenosis in the case of vessels. The same concept was introduced to urology with in vivo experimental studies that showed an improved outcome in the case of drug-eluting MSs [34] .…”

Section: Discussionmentioning

confidence: 99%

The effectiveness of ureteric metal stents in malignant ureteric obstructions: A systematic review

Kallidonis

Kotsiris

Sanguedolce

et al. 2017

Arab Journal of Urology

View full text Add to dashboard Cite

ObjectiveTo review the literature on the effectiveness, safety and long-term patency of ureteric metal mesh stents (MSs), as a variety of MSs have been used for managing malignant ureteric obstruction over the last three decades.Materials and methodsA systematic review using the search string; Ureter∗ AND (stent OR endoprosthesis) AND metal∗ was conducted on PubMed, Scopus, Web of science and Cochrane Library online databases in May 2016. Prospective, retrospective, and comparative studies including MSs were included. The primary endpoint was the patency rate and the secondary endpoint was complications.ResultsIn all, 324 publications were screened and 31 articles were included in the systematic review; 21 prospective and 10 retrospective studies. These studies reported the effectiveness of specific MSs in population studies, in comparative studies among different MSs, as well as among MSs and JJ stents. It should be noted that all comparative studies were retrospective.ConclusionThe experiences with vascular MSs, such as the Wallstent™ (Boston Scientific/Microvasive, Natick, MA, USA), were related to high occlusion rates, due to endoluminal hyperplasia, and long-term disappointing patency. The use of covered MSs designed for the vascular system was also unfavourable. The Memokath 051™ (PNN Medical A/S, Kvistgaard, Denmark) had better patency rates, but also higher migration rates. The long-term results were acceptable and rendered the Memokath 051 as a viable option for the management of malignant ureteric obstruction. The Uventa™ (Taewoong Medical, Seoul, Korea) and Allium™ (Allium Medical Solutions Ltd, Caesarea, Israel) MSs, specifically designed for ureteric placement, provided promising results. Nevertheless, the wide acceptance of these MSs would require well-designed clinical studies and long-term follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

The effectiveness of ureteric metal stents in malignant ureteric obstructions: A systematic review

Kallidonis

Kotsiris

Sanguedolce

et al. 2017

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

“…The high success of the DES in cardiology and interventional radiology led to the adoption of the drug-eluting concept by endourological research in an attempt to prevent significant complications associated with indwelling ureteric stents [ 8 ]. The concept of DCB for use in endourology has been proposed.…”

Section: Introductionmentioning

confidence: 99%

Drug-delivering devices in the urinary tract: A systematic review

Kallidonis

Adamou

Castillo³

et al. 2021

Arab Journal of Urology

View full text Add to dashboard Cite

Objective: : To systematically review the use of drug-eluting stents (DES) and drug-coated balloons (DCB) in urology. Materials and Methods: The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. PubMed, Scopus, Web of science and Cochrane Library online databases were searched in February 2019. Experimental and clinical studies, which included the placement of a DES or dilatation with DCB for investigating their potential use in the urinary tract for the management of ureteric or urethral pathologies, were included. The primary endpoint was to evaluate the current use of DES and DCB in urology. Results: A total of 29 articles were included in the systematic review. A total of 10 studies tested DES or DCB containing anti-proliferative agents (paclitaxel, zotarolimus, sirolimus, halofugione). Antibiotic agent-containing DES were tested in nine studies (triclosan, quinolones, teicoplanin, nitrofurantoin, silver sulfadiazine). A total of eight studies investigated the release of anti-inflammatory agents by DES (ketorolac, indomethacin, EW-7197). Another group studied heparin-eluting stents. Conclusion: Despite the inconclusive outcomes of the three randomised controlled trials, drug-coated/eluting devices constitute a promising field in urology for the prevention of complications associated with conventional stents including pain and encrustation. Preclinical in vitro and in vivo studies have shown their ability to mitigate inflammation, inhibit restenosis and improve pain as indicated by declined use of anti-inflammatory drugs.

show abstract